Jonathan A. Abbott
Virginia–Maryland Regional College of Veterinary Medicine
47 Papers
154 Citations
Jonathan A. Abbott is an academic researcher from Virginia–Maryland Regional College of Veterinary Medicine. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 16, co-authored 44 publications.
Chat about Author
Papers
Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study - A Randomized Clinical Trial
Adrian Boswood,Jens Häggström,Sonya G. Gordon,Gerhard Wess,Rebecca L. Stepien,Mark A. Oyama,Bruce W. Keene,John D. Bonagura,Kristin A. MacDonald,M. Patteson,Sarah Smith,Philip R. Fox,Karen Sanderson,Richard Woolley,Viktor Szatmári,Pierre Menaut,Whitney M. Church,M. L. O'Sullivan,J-P Jaudon,J-G Kresken,John E. Rush,Kirstie A. Barrett,Steven L. Rosenthal,Ashley B. Saunders,Ingrid Ljungvall,M. Deinert,Eric Bomassi,Amara H. Estrada,M. J. Fernández del Palacio,N.S. Moïse,Jonathan A. Abbott,Yoko Fujii,Alan W. Spier,Michael W. Luethy,Roberto A. Santilli,Masami Uechi,Anna Tidholm,P. Watson +37 more
TL;DR: Administration of pimobendan to dogs with MMVD and echocardiographic and radiographic evidence of cardiomegaly results in prolongation of preclinical period and is safe and well tolerated.
270
Prevalence and prognostic importance of pulmonary hypertension in dogs with myxomatous mitral valve disease.
M. Borgarelli,Jonathan A. Abbott,L. Braz-Ruivo,D. Chiavegato,S. Crosara,Kenneth E. Lamb,Ingrid Ljungvall,M. Poggi,R.A. Santilli,Jens Häggström +9 more
TL;DR: In dogs with MMVD, moderate to severe PH worsens outcome and remained significant predictors of worse outcome in the multivariate analysis.
131
International collaborative study to assess cardiovascular risk and evaluate long-term health in cats with preclinical hypertrophic cardiomyopathy and apparently healthy cats: The REVEAL Study.
Philip R. Fox,Bruce W. Keene,Kenneth E. Lamb,Karsten A. Schober,Valérie Chetboul,Virginia Luis Fuentes,Gerhard Wess,Jessie Rose Payne,Daniel F. Hogan,Alison A. Motsinger-Reif,Jens Häggström,Emilie Trehiou-Sechi,Deborah M. Fine-Ferreira,Reid K. Nakamura,Pamela M. Lee,Manreet K. Singh,Wendy A. Ware,Jonathan A. Abbott,Geoffrey Culshaw,Sabine Riesen,M. Borgarelli,Michael B. Lesser,Nicole Van Israël,Etienne Côté,John E. Rush,Barret J. Bulmer,Roberto A. Santilli,Andrea Vollmar,Maribeth J. Bossbaly,Nadine Quick,Claudio Bussadori,Janice M. Bright,Amara H. Estrada,Dan G. Ohad,María Josefa Fernández del Palacio,Jenifer Lunney Brayley,Denise Saretta Schwartz,Christina M. Bové,Sonya G. Gordon,Seung Woo Jung,Paola Brambilla,N. Sydney Moïse,Christopher D. Stauthammer,Rebecca L. Stepien,C. Quintavalla,Christophe Amberger,Ferenc Manczur,Yong Wei Hung,Remo G. Lobetti,Marie de Swarte,A. Tamborini,Carmel T. Mooney,Mark A. Oyama,Andrey Komolov,Yoko Fujii,Romain Pariaut,Masami Uechi,Victoria Yukie Tachika Ohara +57 more
TL;DR: Preclinical HCM/HOCM is a global health problem of cats that carries substantial risk for CHF, ATE, and cardiovascular death, and this finding underscores the need to identify therapies and monitoring strategies that decrease morbidity and mortality.
Conventional echocardiographic assessment of the canine right heart: reference intervals and repeatability.
TL;DR: In this article, the authors defined reference intervals for echocardiographic dimensions of the canine right heart, and quantified measurement variability through calculation of coefficients of variation and repeatability coefficients.
84
Feline hypertrophic cardiomyopathy: an update.
TL;DR: The cause, epidemiology, pathophysiology and therapy of feline hypertrophic cardiomyopathy are reviewed and information that has come to light since this topic was last addressed is emphasized.
75